Evaluation of Soluble Fibrin in Thrombosis Exclusion

NCT ID: NCT02523937

Last Updated: 2019-04-18

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 863 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-09-30
• Study Completion Date: 2018-07-31

Brief Summary

The purpose of the study is to evaluate the performances of Soluble Fibrin assay for exclusion of Pulmonary Embolism and Deep Venous Thrombosis. Secondary objectives are to determine the threshold value from the ROC curves, the possible interest in the positive diagnosis of Venous Thromboembolism (VTE), and to verify the absence of influence of age on the SF results.

Detailed Description

Rationale. Pulmonary embolism (PE) is a major public health problem. D-dimer (D-Di) assay is useful to exclude VTE (DVT and PE) but not specific, requiring irradiating and expensive imaging tests. Preliminary results suggest that the Soluble Fibrin (SF) assay has a sensitivity comparable to the D-Di one, but a higher specificity and thus would limit the use of imaging tests.

Main objective. To evaluate the performances of Soluble Fibrin assay in terms of sensitivity, specificity, negative and positive predictive values for exclusion of Pulmonary Embolism and Deep Venous Thrombosis, in comparison with the D-Dimer test. To determine the threshold value from the ROC curves.

Patients. Inclusion criteria: patients 18 years or older, referred to the Emergency or Internal Medicine Units, for clinically suspected of PE or DVT.

The study was conducted in compliance with French regulation after ethics approval, the authorization for processing personal data (Commission Nationale de l'Informatique et des Libertés, 8, rue Vivienne CS 30223 75083 Paris Cedex 02) decision DR-2015-174 was obtained in April 2015. A preliminary study was performed from April 2015 to September 2015 to define the exclusion criteria.

Comparison with the D-Dimer test. Plasma D-dimer (D-Di) and soluble fibrin are measured in case of low and intermediate clinical probability.

Patients will be classified in two groups, as having or not having PE or DVT on predefined criteria according to the recent guidelines of the European Society of Cardiology by physicians who will be unaware of the SF assay result. PE and DVT have to be confirmed or excluded by the reference algorithm combining clinical probability, D-Dimer, and imaging tests with three month-follow up. The patient who could not be contacted after three months are included in the study and taken into account with the mention "without follow up".

SF Assays. Soluble fibrin is measured by one site, using prototype assays, on both citrated and heparinized frozen plasma taken at baseline. Staff in charge of the assays are not aware of the clinical and diagnosis decisions.

Statistical Analysis of results. The results of D-dimer and Soluble Fibrin assays for the exclusion of PE and DVT will be interpreted on the basis of sensitivity, specificity, negative and predictive values. The ROC curve will be built, the area under the curve will be calculated with its confidence interval. The most suitable threshold will be determined from the curve. Then the diagnosis performances of SF assay will be calculated according to the usual calculations.

The patients under anticoagulant treatment or with an activation of coagulation from known cause are included in the study but analyzed separately.

Number of participants required. A statistical analysis was realized before starting the study. The inclusion of 50 patients with a positive diagnostic of PE or DVT and about 350 patients with an exclusion of PE or DVT will allow calculation of the diagnosis performances of the SF assay and of the area under the ROC curve with an accuracy of 5%. Duration of the study. The total duration of the study is 12 months and up to 18 months if the number of patients could not be obtained.

Conditions

Pulmonary Embolism (PE); Deep Vein Thrombosis (DVT)

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Group without PE or DVT

PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.

The criteria for exclusion of PE or DVT are:

• low or intermediate clinical probability and D-dimer <0,50 µg/mL
• low and moderate clinical probability and negative spiral computed tomography CT and/or proximal lower limb venous compression ultrasonography (US)
• high clinical probability and negative CT and US.

Soluble Fibrin assay will be performed in comparison with D-dimer assays.

Soluble Fibrin

Intervention Type: OTHER

Evaluating the diagnostic performances of the assay in terms of sensitivity, specificity, negative and positive predictive values; from calculation of the area under the curve in comparison with the D-dimers.

Group with PE or DVT

PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.

The criteria for confirmation of PE or DVT are:

• PE on spiral computed tomography (CT)
• proximal deep vein thrombosis on ultrasonography (US).

Soluble Fibrin assay will be performed in comparison with D-dimer assays.

Soluble Fibrin

Intervention Type: OTHER

Evaluating the diagnostic performances of the assay in terms of sensitivity, specificity, negative and positive predictive values; from calculation of the area under the curve in comparison with the D-dimers.

Interventions

Soluble Fibrin

Evaluating the diagnostic performances of the assay in terms of sensitivity, specificity, negative and positive predictive values; from calculation of the area under the curve in comparison with the D-dimers.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• patients with non-opposition to participate in the evaluation,
• outpatients from Emergency or Internal Medicine Units,
• clinically suspected of PE or DVT.

Exclusion Criteria

• patients under 18 years old,
• patients with opposition to participate in the evaluation,
• patients with contraindication to iodinated contrast media.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hôpital Louis Mourier

OTHER

Sponsor Role: collaborator

Hopital Lariboisière

OTHER

Sponsor Role: collaborator

Diagnostica Stago R&D

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Isabelle Mahe, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Université of Paris 7 - Paris Diderot

Geneviève Contant, PhD

Role: STUDY_DIRECTOR

Diagnostica Stago

Locations

Internal Medecine Unit - Adults Pole and Hematology Laboratory Hôpital Louis Mourier (AP-HP)

Colombes, , France

Countries

France

References

Mirshahi S, Soria C, Kouchakji B, Kierzek G, Borg JY, Varin R, Chidiac J, Drouet L, Mirshahi M, Soria J. New combinational assay using soluble fibrin and d-dimer determinations: a promising strategy for identifying patients with suspected venous thromboembolism. PLoS One. 2014 Mar 24;9(3):e92379. doi: 10.1371/journal.pone.0092379. eCollection 2014.

Reference Type: BACKGROUND

PMID: 24664182 (View on PubMed)

Other Identifiers

FSET 2014-A00588-39

Identifier Type: -

Identifier Source: org_study_id